Tumor volumes decreased in the shABCC5 groups (Fig. 4A and B), whereas the shABCC5 plus enzalutamide treatment group showed a synergistic effect with dramatic tumor repression, indicating that the ABCC5 knockdown overcame enzalutamide resistance and restored the sensitivity of resistant cells to enzalutamide. The gene discussed is ABCC5; the disease is neoplasm.